A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Daratumumab (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Sep 2018 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 07 Sep 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.